http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
A Compact Dual-Band MIMO Antenna for Sub-6 GHz 5G Terminals
Dong Guiting,Huang Jianlin,Lin Simin,Chen Zhizhou,Liu Gui 한국전자파학회 2022 Journal of Electromagnetic Engineering and Science Vol.22 No.5
In this paper, a dual-band multiple-input-multiple-output (MIMO) antenna is proposed for fifth-generation (5G) wireless communication terminals. The measured -10 dB impedance bandwidths of 380 MHz (3.34–3.72 GHz) and 560 MHz (4.57–5.13 GHz) can cover the 3.4–3.6 GHz and 4.8–5 GHz 5G bands. The single antenna element of this proposed MIMO is composed of an F-shaped feed strip and an inverted L-shaped radiation strip. A defected ground structure is employed to obtain a good isolation performance, whereby the measured isolation between the antenna elements is observed to be larger than 23 dB. The measured total radiation efficiencies at 3.5 GHz and 4.9 GHz are 76.65% and 71.93%, respectively. Besides, the calculated envelope correlation coefficients (ECC) are less than 0.00125 and 0.01164 at the low-frequency and high-frequency bands, respectively. Furthermore, the specific absorption ratio (SAR) analysis of the antenna verifies that it qualifies for 5G terminals.
Low-Intensity Shock Wave Therapy and Its Application to Erectile Dysfunction
Hongen Lei,Jing Liu,Huixi Li,Lin Wang,Yongde Xu,Wenjie Tian,Guiting Lin,Zhongcheng Xin 대한남성과학회 2013 The World Journal of Men's Health Vol.31 No.3
Although phosphodiesterase type 5 inhibitors (PDE5Is) are a revolution in the treatment of erectile dysfunction (ED) and have been marketed since 1998, they cannot restore pathological changes in the penis. Low-energy shock wave therapy (LESWT) has been developed for treating ED, and clinical studies have shown that LESWT has the potential to affect PDE5I non-responders with ED with few adverse effects. Animal studies have shown that LESWT significantly improves penile hemodynamics and restores pathological changes in the penis of diabetic ED animal models. Although the mechanisms remain to be investigated, recent studies have reported that LESWT could partially restore corpus cavernosum fibromuscular pathological changes, endothelial dysfunction, and peripheral neuropathy. LESWT could be a novel modality for treating ED, and particularly PDE5I non-responders with organic ED, in the near future. However, further extensive evidence-based basic and clinical studies are needed. This review intends to summarize the scientific background underlying the effect of LESWT on ED.
Yuanchong Chen,Dong Xu,Mingjian Ruan,Haixia Li,Guiting Lin,Gang Song 대한비뇨의학회 2023 Investigative and Clinical Urology Vol.64 No.4
Purpose: To evaluate the predictive performance of the prostate health index (PHI) and PHI density (PHID), for clinically significant prostate cancer (csPCa) in patients with a PI-RADS score ≤3. Materials and Methods: Patients tested for total prostate-specific antigen (tPSA, ≤100 ng/mL), free PSA (fPSA), and p2PSA at Peking University First Hospital were prospectively enrolled. Possible predictive factors of csPCa were analyzed using the receiver operating characteristic (ROC) curve. Results were expressed as area under the curve (AUC) with 95% confidence intervals (CI). The cutoff values of PHI and PHID were determined. Results: We enrolled 222 patients in this study. The prevalence of csPCa in the PI-RADS ≤3 subgroup (n=89) was 22.47% (20/89). Age, tPSA, F/T, prostate volume, PSA density, PHI, PHID, and PI-RADS score were significantly associated with csPCa. PHID (AUC: 0.829 [95% CI: 0.717–0.941]) was the best predictor of csPCa. PHID >0.956 was set as the threshold of suspicious csPCa with a sensitivity of 85.00% and a specificity of 73.91%, avoiding 94.44% of unnecessary biopsies but missing 15.00% csPCa. A threshold of PHI ≥52.83 showed the same sensitivity but a rather lower specificity of 65.22% that avoided 93.75% of unnecessary biopsies. Conclusions: PHI and PHID have the best predictive performance of csPCa in patients with PI-RADS score ≤3. A threshold value of PHID ≥0.956 may be used as the criterion for biopsy in these patients.